CLASS II ONGOING Device recall · Reported 13 Nov 2024 · FDA Enforcement Report

The Access Cortisol assay is a paramagnetic particle recalled

Beckman Coulter is recalling The Access Cortisol assay is a paramagnetic particle, chemiluminescent immunoassay for. The recall was initiated on 30 Sep 2024 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesUDI/DI 15099590231118, all lots
Quantity recalled149 units

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

Recall details

Recall number
Z-0313-2025
FDA event ID
95473
Recalling firm
Beckman Coulter, Chaska, MN
Classification
Class II
Status
Ongoing
Recall initiated
30 Sep 2024
FDA classified
6 Nov 2024
Reported
13 Nov 2024
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Potency & Assay

Timeline

30 Sep 2024Recall initiated by company
6 Nov 2024Classified by FDA+37 days
13 Nov 2024Published in enforcement report+7 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

The Access Cortisol assay protocol file (APF) applies an incorrect calibration curve acceptance parameter at the S1 calibrator level that can lead to a high rate of calibration failures which can vary by reagent lot number. Calibration failure would lead to delay of measurement results reporting and potential injuries.

Potency and specification recalls happen when a batch tests outside its approved limits for strength, purity or dissolution, which can mean the dose delivered is higher or lower than labelled.

Product as listed by the FDA

The Access Cortisol assay is a paramagnetic particle, chemiluminescent immunoassay for the quantitative determination of cortisol levels in human serum, plasma (heparin, EDTA) and urine using the Access Immunoassay Systems.

Where it was distributed

Worldwide distribution.

Questions about this recall

Why was it recalled?

The Access Cortisol assay protocol file (APF) applies an incorrect calibration curve acceptance parameter at the S1 calibrator level that can lead to a high rate of calibration failures which can vary by reagent lot number. Calibration failure would lead to delay of measurement results reporting and potential injuries.

Which lots are affected?

UDI/DI 15099590231118, all lots

Where was it sold?

Worldwide distribution.

What should I do if I have it?

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Beckman Coulter

All 336

Other Test Kits & Diagnostics recalls

All 2,663